Management of Anemia and Neutropenia in Multiple Myeloma Patients

Immediate Management of Severe Anemia

The European Society for Medical Oncology recommends urgent red blood cell transfusion for patients with severe anemia (hemoglobin < 7-8 g/dL) and hemodynamic instability, to rapidly improve hemoglobin levels and prevent cardiovascular collapse 1, 2
A hemoglobin level of 3.6 g/dL with tachycardia represents severe symptomatic anemia requiring urgent correction to prevent end-organ damage 1, 2
Transfusion provides rapid hemoglobin increase, unlike erythropoiesis-stimulating agents (ESAs) which take weeks to show effect 1, 2

The International Myeloma Society recommends immediate broad-spectrum antibiotics for patients with fever or clinical signs of infection in the setting of neutropenia 4, 5
G-CSF (filgrastim) should be administered if the patient has severe neutropenia (ANC < 500 cells/mL) or grade 2-3 neutropenia complicated by infection 3
Dose reduction of 25-50% is recommended for grade 3-4 neutropenia or grade 2-3 neutropenia complicated by infection in patients receiving lenalidomide-based or bortezomib-based therapy 3, 6

Antimicrobial prophylaxis should be strongly considered given the dual risk factors of neutropenia and multiple myeloma-related immune dysfunction 4, 5
Trimethoprim-sulfamethoxazole for Pneumocystis jirovecii prophylaxis during high-dose dexamethasone therapy 3, 5
Acyclovir or valacyclovir for herpes-zoster virus prophylaxis during proteasome inhibitor-based therapy 4, 5

The European Hematology Association recommends ESAs (erythropoietin-α, erythropoietin-β, or darbepoetin) for hemoglobin < 10 g/dL to reduce future transfusion requirements 1, 2, 4
ESAs should be administered at the lowest possible dose to maintain hemoglobin around 12 g/dL (below 14 g/dL to avoid thromboembolic complications and hypertension) 2, 4
Check iron studies (transferrin saturation) before initiating ESAs, as iron deficiency reduces ESA response 2, 6